Naprosumo (Naproxen)

Naproxen blocks the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for producing prostaglandins. By lowering prostaglandin levels, it diminishes inflammation, pain signaling, and fever responses, providing the therapeutic effects typical of nonsteroidal anti‑inflammatory drugs.

The appropriate dose of Naprosumo is determined by the prescribing clinician based on the individual’s medical condition, age, weight, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety of naproxen in pregnancy and lactation is not fully established. It should only be used if the potential benefit outweighs the risk, and after consultation with a healthcare provider. Breastfeeding mothers should discuss possible exposure with their physician.

To request Naprosumo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naprosumo (naproxen) offers a longer half‑life than ibuprofen, allowing twice‑daily dosing for many patients. Its efficacy in pain and inflammation is comparable to other NSAIDs, but individual tolerance, cardiovascular risk profile and gastrointestinal safety may differ, so clinicians choose based on patient‑specific factors.

Naprosumo should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat and direct sunlight, and ensure they are out of reach of children.

Naprosumo is taken orally, usually with a full glass of water. It can be taken with or without food, but taking it with food may reduce stomach irritation. Patients should swallow the tablet whole and not crush or chew it unless directed by a healthcare professional.

Serious risks include gastrointestinal bleeding or ulceration, cardiovascular events such as heart attack or stroke, severe kidney injury, and rare hypersensitivity reactions like anaphylaxis. Patients should seek immediate medical attention if they notice signs of serious bleeding, chest pain, sudden weakness, or allergic reactions.

Naprosumo is contraindicated in individuals with known hypersensitivity to naproxen or other NSAIDs, active gastrointestinal bleeding or ulcer disease, severe heart failure, and those who have had a recent myocardial infarction. It should also be avoided in patients on certain anticoagulants unless closely monitored.